Skip to main content

Table 1 Correlation between the expressions of miR-17 and miR-92 families and the clinicopathological features of NSCLC patients

From: The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer

Clinicopathological factors Expression level of 6 miRNAsa χ2 value P value
High (n = 20) Low (n = 19)
Histological type Adenocarcinoma 12 10 0.216 0.642
Squamous carcinoma 8 9
Gender Male 14 15 0.407 0.523
Female 6 4
Age (years) <60 9 7 0.265 0.607
≥60 11 12
Smoking Nonsmoker 8 8 0.019 0.891
Smoker 12 11
TNM Clinical stage IIIB 5 8 1.288 0.256
IV 15 11
Chemotherapy regimensb DDP + TXT 9 6 0.745 0.689
DDP + GEM 6 7
DDP + NVB 5 6
Chemotherapy responsec CR + PR 7 13 4.366 0.036*
SD + PD 13 6
  1. (* P < 0.05)
  2. aExpression level of 6 miRNAs (miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25) was used the sum of scores as categorical variables, where each miRNA was dichotomised and its categories represented by the score of 0 or 1 as follows: score 0 (low risk) = miR-17, miR-20a, miR-20b, miR-92a, miR-92b, miR-25 levels ≥ median; score 1(high risk) = converse of criteria for score 0
  3. bDDP cisplatin, TXT docetaxel, GEM gemcitabine, NVB vinorelbine
  4. cCR complete response, PR partial response, SD stable disease, PD progressive disease